Allspring Global Investments Holdings LLC Cuts Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Allspring Global Investments Holdings LLC reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,927 shares of the medical equipment provider’s stock after selling 4,806 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Lantheus were worth $4,335,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Tucker Asset Management LLC grew its stake in shares of Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Lantheus by 60.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 160 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the last quarter. Covestor Ltd lifted its position in shares of Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 203 shares in the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new position in shares of Lantheus in the 2nd quarter worth approximately $46,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on LNTH shares. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. B. Riley increased their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $104.71.

Insider Activity at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. In the last ninety days, insiders sold 94,545 shares of company stock worth $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Lantheus Trading Up 2.4 %

Shares of LNTH opened at $63.81 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $100.85. The business has a 50-day moving average of $60.81 and a 200 day moving average of $62.97. The firm has a market cap of $4.37 billion, a P/E ratio of 13.75 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.